THB335 Lower Dose

Phase 2

THB335 Lower Dose is one of 4 therapeutic programs targeting Chronic Spontaneous Urticaria (CSU). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Spontaneous Urticaria (CSU)Not yet recruiting

Chronic Spontaneous Urticaria (CSU)Phase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Chronic Spontaneous Urticaria (CSU)

#DrugCompanyPhaseTrials

Rhapsido

Novartis

Phase 3

2 2

THB335 Lower Dose

CCalixis Inc.

Phase 2

1 3

Alpha-0261

AAlphaMol Science Ltd. (Shanghai)

Phase 1

1 4

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Chronic Spontaneous Urticaria (CSU)

NCT07766499

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Standard-of-Care Treatment

Not yet recruiting·CCalixis Inc.·Phase 2·NCT07766499·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for THB335 Lower Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for THB335 Lower Dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Calixis Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCalixis Inc.

THB335 Lower Dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

References

Drug Info

Quick Facts

Related News